Comments on: UBS Life Science Conference Dominated by Wall Street Drama

By: Robin Lipschitz, MD

Robin Lipschitz, MD — Fri, 02 Oct 2009 18:00:31 +0000

What was the overall response to Angioblast regarding their pipeline cardiac regenerative product?
Looks like Mesoblast (on Australian stock exchange and controls)1/3 Angio.) should have benefitted greatly but seems to be lagging despite good preliminary data on their cardiac and musculoskeletal fronts.

By: Wall Street Gloom Dominated UBS Global Health Conference « Audrey’ s Network

Tue, 30 Sep 2008 23:02:57 +0000

[...] ago.”You can read more at http://pharmexec.findpharma.com/ in the article entitled “UBS Life Science Conference Dominated by Wall Street Drama“. I also commented on the Roche breakout sessions when attendees have the opportunities to [...]

By: Ex-Pfizer

Ex-Pfizer — Wed, 24 Sep 2008 13:33:38 +0000

Ian Read presented a shell game. There is no pipeline or strategy at Pfizer, just a bunch of mumbo jumbo about rehashing old products with no commercial value. A total joke. Reassuring?????